Semaglutide showed cardiovascular outcome improvements in the SELECT trial (in non-diabetic overweight and obese patients), and tirzepatide showed similar benefits in the SURMOUNT-MMO trial
Yang J, Shang J, Yang L, Wei D, Wang X, Deng Q, et al
Cng dng chnh l lm trng da, m nm, tn nhang v gip da mm mi, mn mng hn
So it it really is the the multidisciplinary approach too, particularly with obesity treatment because like doctor Frank said, I think earlier, you know, this there there isnt one type of patient
La mayora de los pacientes encuentran el proceso de inyeccin fcil y manejable con la gua adecuada
This normalization in IGF-1 in turn resulted in a normalization of the elevated GH levels